Treatment of primary localised cutaneous amyloidosis with cyclophosphamide.
The study was undertaken to evaluate the efficacy of cyclophosphamide in primary localised cutaneous amyloidosis. Thirty-six patients of primary localised cutaneous amyloidosis were treated with cyclophosphamide 50 mg. tablets orally daily for a period of six months. Most of the patients following the therapy showed marked improvement in respect of itching, pigmentation and sizes of the popular lesions. Side effects of cyclophosphamide were very low.